Published in Pharma Law Weekly, August 16th, 2005
The grant of this U.S. patent extends Amrad's intellectual property portfolio relating to its collaborative project with Merck & Co., Inc., for the development of a potential new treatment for asthma and other types of respiratory disease. Amrad partnered this project with Merck in June 2003 in a deal potentially worth U.S.$112 million, plus royalties on product sales. The project has made excellent progress with Amrad already receiving payments totalling U.S.$15 million.
Andrew Nash, Amrad Interim...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly